Description

New ISIN number INE331C01025 assigned for sub-divided equity shares of Welcure Drugs & Pharmaceuticals Ltd, effective from October 16, 2025.

Summary

BSE has announced the new ISIN number for Welcure Drugs & Pharmaceuticals Ltd (Scrip Code: 524661) following the sub-division of equity shares. The new ISIN number INE331C01025 will be effective for all trades executed on and from October 16, 2025 (Ex-Date). This follows the company’s decision to sub-divide its equity shares from a face value of Rs. 10/- to Re. 1/-.

Key Points

  • New ISIN number: INE331C01025
  • Company: Welcure Drugs & Pharmaceuticals Ltd
  • Scrip Code: 524661
  • Corporate action: Sub-division of equity shares from Rs. 10/- to Re. 1/-
  • New face value: Re. 1/- per equity share
  • Ex-Date: October 16, 2025
  • DR Number: 737/2025-2026
  • Notice continues from previous exchange notice dated October 13, 2025 (Notice No. 20251013-18)

Regulatory Changes

No new regulatory changes introduced. This is a standard corporate action implementation notice.

Compliance Requirements

  • Trading members must update their systems with the new ISIN number INE331C01025
  • All trades executed on or after October 16, 2025 must use the new ISIN
  • Systems should be configured to handle the new face value of Re. 1/- per share
  • Members should ensure proper tracking and settlement using the updated ISIN

Important Dates

  • October 13, 2025: Original notice issued (Notice No. 20251013-18)
  • October 14, 2025: Current notice date announcing new ISIN
  • October 16, 2025: Ex-Date - New ISIN becomes effective for trading

Impact Assessment

Market Impact: Medium - The share sub-division increases the number of shares outstanding by 10x while reducing the price per share proportionally. This typically improves liquidity and makes shares more accessible to retail investors.

Operational Impact: Medium - Trading members and market participants must update their systems, databases, and records with the new ISIN. Existing shareholders will see their holdings adjusted automatically, with 10 new shares of Re. 1/- for every 1 old share of Rs. 10/-.

Investor Impact: Neutral to Positive - While the total investment value remains unchanged, the lower price per share post-subdivision may attract more retail participation and improve trading activity.

Impact Justification

Routine corporate action involving ISIN change due to share sub-division. Affects existing shareholders and trading systems but is a standard procedural change.